The funding was awarded through the Capability and Innovation Fund Pool D grant to develop a global transaction platform for UK businesses.
"Form3’s FI API payment technology and Ebury’s global SME transaction services are already disrupting payments and forex. Our plan is to combine these unique capabilities to significantly disrupt the market and give UK SMEs access to these services at scale through our FI clients, enabling UK SMEs to grow their businesses internationally and focus on their core businesses."
EarthSense has secured grant funding from Innovate UK to deliver a partnership air quality project in Wolverhampton.
"Using the information from the app, users can choose to avoid certain high pollution areas, reducing the amount of emissions inhaled, and hopefully divert traffic away from those areas, thereby reducing the levels of pollution – a positive result for everyone."
The grant will fund an online platform providing researchers with access to AI models and algorithms.
"This partnership and funding clearly indicate the importance and value of artificial intelligence as a new approach to support UK SMEs and reinvigorate drug discovery. Our aim is to help deliver a platform which is of high value to UK SMEs to advance their own drug discovery projects faster and more efficiently by accessing otherwise inaccessible, complex technical expertise"
The funding will support a consortium project developing open source software for the UK healthcare sector.
"We’re thrilled to have been given the opportunity by Innovate UK to prove that professional open source is the only viable solution to the NHS’s complex software needs. Innovate UK understood that we have ambitious aims to transform the NHS’s approach to digital technology, helping to create software that is the perfect clinical fit for today and adaptable for tomorrow saving lives and money simultaneously."
The company has obtained capital from the NHS England funded initiative to support pre-clinical development.
"After several years of research in collaboration with Mogrify, it is great to see our transdifferentiated cartilage cells gain commercial traction from grants such as the SBRI Healthcare and (pre-)clinical partners."
